CL2021001636A1 - Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar - Google Patents
Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonarInfo
- Publication number
- CL2021001636A1 CL2021001636A1 CL2021001636A CL2021001636A CL2021001636A1 CL 2021001636 A1 CL2021001636 A1 CL 2021001636A1 CL 2021001636 A CL2021001636 A CL 2021001636A CL 2021001636 A CL2021001636 A CL 2021001636A CL 2021001636 A1 CL2021001636 A1 CL 2021001636A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pharmaceutical composition
- arterial hypertension
- pulmonary arterial
- aprocitentan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con dosis elevadas de macitentán, o sales farmacéuticamente aceptables, solvatos, hidratos o formas morfológicas de este, o de aprocitentán, y una composición farmacéutica que los comprende, para uso en el tratamiento y/o prevención de la hipertensión arterial pulmonar (HAP), y para la elaboración de un medicamento. Describe también un régimen de dosificación para el mismo uso, así como una combinación de macitentán, o de aprocitentán, con otro agente activo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2018086724 | 2018-12-21 | ||
EP2019051830 | 2019-01-25 | ||
EP2019060151 | 2019-04-18 | ||
EP2019066494 | 2019-06-21 | ||
EP2019067186 | 2019-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001636A1 true CL2021001636A1 (es) | 2022-02-18 |
Family
ID=69147670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001636A CL2021001636A1 (es) | 2018-12-21 | 2021-06-18 | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar |
Country Status (18)
Country | Link |
---|---|
US (3) | US11234980B2 (es) |
EP (1) | EP3897646B1 (es) |
JP (1) | JP2022512493A (es) |
KR (1) | KR20210109558A (es) |
CN (1) | CN113194953A (es) |
AU (1) | AU2019410727A1 (es) |
BR (1) | BR112021011999A2 (es) |
CA (1) | CA3123990A1 (es) |
CL (1) | CL2021001636A1 (es) |
CO (1) | CO2021007186A2 (es) |
IL (1) | IL284136A (es) |
JO (1) | JOP20210153A1 (es) |
MA (1) | MA54522A (es) |
MX (1) | MX2021007455A (es) |
PH (1) | PH12021551371A1 (es) |
SG (1) | SG11202105098VA (es) |
WO (1) | WO2020128017A1 (es) |
ZA (1) | ZA202105111B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017400276B2 (en) * | 2017-02-27 | 2024-01-11 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
MX2021007455A (es) | 2018-12-21 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar. |
TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100432070C (zh) | 2000-12-18 | 2008-11-12 | 埃科特莱茵药品有限公司 | 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用 |
SI1928409T1 (sl) | 2005-09-12 | 2012-12-31 | Actelion Pharmaceuticals Ltd. | Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
SI3300729T1 (sl) | 2008-08-13 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Terapevtski sestavki, ki vsebujejo macitentan |
CA3043283A1 (en) * | 2016-11-10 | 2018-05-17 | Arena Pharmaceuticals, Inc. | Methods of treating pah with combinations of ralinepag and other agents |
WO2018153925A1 (en) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Stable pharmaceutical compositions comprising macitentan |
AU2017400276B2 (en) | 2017-02-27 | 2024-01-11 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
MX2021007455A (es) | 2018-12-21 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar. |
TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
BR112022010098A2 (pt) | 2019-11-26 | 2022-09-06 | Actelion Pharmaceuticals Ltd | Composição farmacêutica para o tratamento de doença vascular pulmonar e/ou disfunção cardíaca em pacientes submetidos à cirurgia de fontan |
-
2019
- 2019-12-20 MX MX2021007455A patent/MX2021007455A/es unknown
- 2019-12-20 CN CN201980084868.5A patent/CN113194953A/zh active Pending
- 2019-12-20 EP EP19832954.2A patent/EP3897646B1/en active Active
- 2019-12-20 BR BR112021011999-0A patent/BR112021011999A2/pt unknown
- 2019-12-20 CA CA3123990A patent/CA3123990A1/en active Pending
- 2019-12-20 AU AU2019410727A patent/AU2019410727A1/en active Pending
- 2019-12-20 MA MA054522A patent/MA54522A/fr unknown
- 2019-12-20 JO JOP/2021/0153A patent/JOP20210153A1/ar unknown
- 2019-12-20 WO PCT/EP2019/086754 patent/WO2020128017A1/en unknown
- 2019-12-20 SG SG11202105098VA patent/SG11202105098VA/en unknown
- 2019-12-20 KR KR1020217022508A patent/KR20210109558A/ko unknown
- 2019-12-20 JP JP2021533836A patent/JP2022512493A/ja active Pending
-
2021
- 2021-03-02 US US17/189,881 patent/US11234980B2/en active Active
- 2021-05-31 CO CONC2021/0007186A patent/CO2021007186A2/es unknown
- 2021-06-10 PH PH12021551371A patent/PH12021551371A1/en unknown
- 2021-06-17 IL IL284136A patent/IL284136A/en unknown
- 2021-06-18 CL CL2021001636A patent/CL2021001636A1/es unknown
- 2021-07-20 ZA ZA2021/05111A patent/ZA202105111B/en unknown
- 2021-10-29 US US17/515,132 patent/US11464777B2/en active Active
-
2022
- 2022-09-27 US US17/953,530 patent/US20230020241A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022512493A (ja) | 2022-02-04 |
MX2021007455A (es) | 2021-08-05 |
CO2021007186A2 (es) | 2021-06-10 |
SG11202105098VA (en) | 2021-06-29 |
PH12021551371A1 (en) | 2021-11-29 |
US11464777B2 (en) | 2022-10-11 |
ZA202105111B (en) | 2023-03-29 |
BR112021011999A2 (pt) | 2021-09-08 |
CN113194953A (zh) | 2021-07-30 |
CA3123990A1 (en) | 2020-06-25 |
IL284136A (en) | 2021-08-31 |
MA54522A (fr) | 2022-03-23 |
EP3897646B1 (en) | 2024-05-22 |
US20220096476A1 (en) | 2022-03-31 |
US20230020241A1 (en) | 2023-01-19 |
US11234980B2 (en) | 2022-02-01 |
WO2020128017A1 (en) | 2020-06-25 |
US20210196715A1 (en) | 2021-07-01 |
EP3897646A1 (en) | 2021-10-27 |
KR20210109558A (ko) | 2021-09-06 |
JOP20210153A1 (ar) | 2023-01-30 |
AU2019410727A1 (en) | 2021-08-12 |
TW202034923A (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
CL2016002848A1 (es) | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd | |
CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CO2021011046A2 (es) | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
CL2018003391A1 (es) | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. | |
CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
CL2022000095A1 (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
CL2014003326A1 (es) | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. | |
CL2018003707A1 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo. | |
CO2017000354A2 (es) | Desmopresina estabilizada | |
AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
AR108280A1 (es) | Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo | |
AR108792A1 (es) | Composiciones que comprenden timolol | |
AR099330A1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
CO2019008347A2 (es) | Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla | |
DOP2019000233A (es) | Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta | |
AR115293A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
CO2020000292A2 (es) | Preparación medicinal combinada para tratar infecciones virales |